These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 11158198)

  • 21. Chemoprevention of breast cancer with fenretinide.
    Torrisi R; Decensi A; Formelli F; Camerini T; De Palo G
    Drugs; 2001; 61(7):909-18. PubMed ID: 11434448
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mammographic patterns in breast cancer chemoprevention with fenretinide (4-HPR).
    Cassano E; Coopmans de Yoldi G; Ferranti C; Costa A; Mascotti G; De Palo G; Veronesi U
    Eur J Cancer; 1993; 29A(15):2161-3. PubMed ID: 8297658
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Breakthrough in breast cancer chemoprevention].
    Kahán Z; Thurzó L
    Orv Hetil; 2003 Mar; 144(13):597-603. PubMed ID: 12728784
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fenretinide (4-HPR): a preventive chance for women at genetic and familial risk?
    Cazzaniga M; Varricchio C; Montefrancesco C; Feroce I; Guerrieri-Gonzaga A
    J Biomed Biotechnol; 2012; 2012():172897. PubMed ID: 22500077
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Preventing hormone-dependent breast cancer in high-risk women.
    Vogel VG; Lo S
    J Natl Cancer Inst; 2003 Jan; 95(2):91-3. PubMed ID: 12529335
    [No Abstract]   [Full Text] [Related]  

  • 26. Prospects of chemoprevention of human cancers with the synthetic retinoid fenretinide.
    Costa A; Formelli F; Chiesa F; Decensi A; De Palo G; Veronesi U
    Cancer Res; 1994 Apr; 54(7 Suppl):2032s-2037s. PubMed ID: 8137334
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Chemoprevention trial of contralateral breast cancer with fenretinide. Rationale, design, methodology, organization, data management, statistics and accrual.
    De Palo G; Camerini T; Marubini E; Costa A; Formelli F; Del Vecchio M; Mariani L; Miceli R; Mascotti G; Magni A; Campa T; Di Mauro MG; Attili A; Maltoni C; Del Turco MR; Decensi A; D'Aiuto G; Veronesi U
    Tumori; 1997; 83(6):884-94. PubMed ID: 9526578
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ribociclib in HR-positive, HER2-negative breast cancer.
    Burki TK
    Lancet Oncol; 2016 Nov; 17(11):e482. PubMed ID: 27746106
    [No Abstract]   [Full Text] [Related]  

  • 29. Quality control for HPLC assay and surrogate end point biomarkers from the fenretinide (4-HPR) breast cancer prevention trial.
    Formelli F
    J Cell Biochem Suppl; 2000; 34():73-9. PubMed ID: 10762018
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adiponectin: a risk biomarker and attractive target for chemoprevention.
    Fabian CJ
    J Clin Oncol; 2012 Jan; 30(2):124-6. PubMed ID: 22162567
    [No Abstract]   [Full Text] [Related]  

  • 31. Chemoprevention of breast cancer.
    Costa A; Sacchini V; Bonanni B; D'Aiuto G
    Eur J Cancer Prev; 1994 Jul; 3(4):361-4. PubMed ID: 7950891
    [No Abstract]   [Full Text] [Related]  

  • 32. The synthetic retinoid fenretinide lowers plasma insulin-like growth factor I levels in breast cancer patients.
    Torrisi R; Pensa F; Orengo MA; Catsafados E; Ponzani P; Boccardo F; Costa A; Decensi A
    Cancer Res; 1993 Oct; 53(20):4769-71. PubMed ID: 8402658
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Breast cancer adjuvants: results of a DUR (drug utilization research) study].
    Nuzzo A
    Suppl Tumori; 2004; 3(4):S86-7. PubMed ID: 15206223
    [No Abstract]   [Full Text] [Related]  

  • 34. What is the value of the 21 gene recurrence score in HER2-negative patients?
    Rosman M; Mylander WC; Tafra L
    J Clin Oncol; 2010 Nov; 28(31):e647; author reply e648. PubMed ID: 20876423
    [No Abstract]   [Full Text] [Related]  

  • 35. Synthetic retinoid fenretinide in breast cancer chemoprevention.
    Bonanni B; Lazzeroni M; Veronesi U
    Expert Rev Anticancer Ther; 2007 Apr; 7(4):423-32. PubMed ID: 17428163
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Leisure-time physical activity and breast cancer risk defined by estrogen and progesterone receptor status--the Japan Public Health Center-based Prospective Study.
    Suzuki R; Iwasaki M; Yamamoto S; Inoue M; Sasazuki S; Sawada N; Yamaji T; Shimazu T; Tsugane S;
    Prev Med; 2011; 52(3-4):227-33. PubMed ID: 21295062
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Re: Italian randomized trial among women with hysterectomy: tamoxifen and hormone-dependent breast cancer in high-risk women.
    Ménard S; Casalini P; Tagliabue E; Pupa SM; Balsari A
    J Natl Cancer Inst; 2003 Jun; 95(12):917-8; author reply 918-9. PubMed ID: 12813176
    [No Abstract]   [Full Text] [Related]  

  • 38. [Basic Consensus on endocrinotherapy for breast cancer].
    Jiang ZF; Xu BH; Song ST
    Zhonghua Zhong Liu Za Zhi; 2006 Mar; 28(3):238-9. PubMed ID: 16875616
    [No Abstract]   [Full Text] [Related]  

  • 39. Estrogen receptor status of primary breast cancer is predictive of estrogen receptor status of contralateral breast cancer.
    Swain SM; Wilson JW; Mamounas EP; Bryant J; Wickerham DL; Fisher B; Paik S; Wolmark N
    J Natl Cancer Inst; 2004 Apr; 96(7):516-23. PubMed ID: 15069113
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognosis and treatment of patients with breast tumors of one centimeter or less and negative axillary lymph nodes.
    Fisher B; Dignam J; Tan-Chiu E; Anderson S; Fisher ER; Wittliff JL; Wolmark N
    J Natl Cancer Inst; 2001 Jan; 93(2):112-20. PubMed ID: 11208880
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.